<code id='58776EB114'></code><style id='58776EB114'></style>
    • <acronym id='58776EB114'></acronym>
      <center id='58776EB114'><center id='58776EB114'><tfoot id='58776EB114'></tfoot></center><abbr id='58776EB114'><dir id='58776EB114'><tfoot id='58776EB114'></tfoot><noframes id='58776EB114'>

    • <optgroup id='58776EB114'><strike id='58776EB114'><sup id='58776EB114'></sup></strike><code id='58776EB114'></code></optgroup>
        1. <b id='58776EB114'><label id='58776EB114'><select id='58776EB114'><dt id='58776EB114'><span id='58776EB114'></span></dt></select></label></b><u id='58776EB114'></u>
          <i id='58776EB114'><strike id='58776EB114'><tt id='58776EB114'><pre id='58776EB114'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:8753
          BiTE Bridge
          Illustration of a BiTE, Amgen's bispecific antibodies Amgen

          In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

          Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

          advertisement

          “We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more
          Ultragenyx gene therapy for rare liver ailment succeeds in late
          Ultragenyx gene therapy for rare liver ailment succeeds in late

          JonathanWiggs/GlobeStaffUltragenyxsaidThursdayafternoonthatitsgenetherapyforarareliverailment,glycog

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          Readout LOUD podcast: ASCO preview, a Duchenne trial failure

          WhichpresentationsareworthcatchingatASCOthisweekend?Whatisexon-skipping?Andhowdoyoupronouncebronchie